0001492298-23-000016.txt : 20230614 0001492298-23-000016.hdr.sgml : 20230614 20230614164520 ACCESSION NUMBER: 0001492298-23-000016 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20230614 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20230614 DATE AS OF CHANGE: 20230614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sabra Health Care REIT, Inc. CENTRAL INDEX KEY: 0001492298 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 272560479 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34950 FILM NUMBER: 231014707 BUSINESS ADDRESS: STREET 1: 18500 VON KARMAN STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 BUSINESS PHONE: 888-393-8248 MAIL ADDRESS: STREET 1: 18500 VON KARMAN STREET 2: SUITE 550 CITY: IRVINE STATE: CA ZIP: 92612 8-K 1 sbra-20230614.htm 8-K sbra-20230614
false000149229800014922982023-06-142023-06-14

  
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): June 14, 2023
SABRA HEALTH CARE REIT, INC.
(Exact name of registrant as specified in its charter)
 
Maryland 001-34950 27-2560479
(State of
Incorporation)
 (Commission
File Number)
 (I.R.S. Employer
Identification No.)
 
18500 Von Karman AvenueSuite 550
Irvine
CA
92612
(Address of principal executive offices)(Zip Code)
Registrant's telephone number including area code: (888393-8248  
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:  
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, $0.01 par valueSBRAThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.07
Submission of Matters to a Vote of Security Holders.
(a) The annual meeting of stockholders of the Company (the “Annual Meeting”) was held on June 14, 2023.
(b) At the Annual Meeting, the Company’s stockholders (i) elected the eight nominees identified in the table below to the Board of Directors of the Company to serve until the Company’s 2024 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified (“Election of Directors”), (ii) ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 (“Auditor Ratification”), (iii) approved, on an advisory basis, the compensation of the Company’s named executive officers as set forth in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 24, 2023 (“Advisory Compensation Vote”), and (iv) approved, on an advisory basis, a one-year frequency for future advisory votes on named executive officer compensation (“Advisory Frequency Vote”). Set forth below are the final voting tallies for the Annual Meeting:

Election of Directors
For
Against
Abstain
Broker Non-Votes
Craig A. Barbarosh
162,465,17220,910,431278,10719,852,000
Katie Cusack
181,594,0721,818,582241,05619,852,000
Michael J. Foster
177,034,4136,341,006278,29119,852,000
Lynne S. Katzmann
179,479,2313,926,471248,00819,852,000
Ann Kono
181,594,6471,795,306263,75719,852,000
Jeffrey A. Malehorn
180,490,7872,894,640268,28319,852,000
Richard K. Matros
174,321,9569,047,392284,36219,852,000
Clifton J. Porter II
180,847,1092,511,833294,76819,852,000

Auditor Ratification
For
Against
Abstain
Broker Non-Votes
201,471,3091,833,522200,879

Advisory Compensation Vote
For
Against
Abstain
Broker Non-Votes
173,851,7469,364,923437,04119,852,000

Advisory Frequency Vote

1 Year
2 Years
3 Years
Abstain
Broker Non-Votes
177,124,473221,3366,010,377297,52419,852,000
(d) On June 14, 2023, following the Annual Meeting, the Company’s Board of Directors agreed that an advisory vote on named executive compensation would be held annually until the next required vote on the frequency of such votes.





SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
SABRA HEALTH CARE REIT, INC.
Date: June 14, 2023/S/ MICHAEL COSTA
Name: Michael Costa
Title: Chief Financial Officer, Secretary and Executive Vice President




EX-101.SCH 2 sbra-20230614.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 sbra-20230614_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company Document Period End Date Document Period End Date Soliciting Material Soliciting Material Current Fiscal Year End Date Current Fiscal Year End Date Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Security Exchange Name Security Exchange Name EX-101.PRE 4 sbra-20230614_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
Jun. 14, 2023
Cover [Abstract]  
Title of 12(b) Security Common stock, $0.01 par value
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 14, 2023
Entity Registrant Name SABRA HEALTH CARE REIT, INC.
Entity Central Index Key 0001492298
Entity Incorporation, State or Country Code MD
Entity File Number 001-34950
Entity Tax Identification Number 27-2560479
Entity Address, Address Line One 18500 Von Karman Avenue
Entity Address, Address Line Two Suite 550
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92612
City Area Code 888
Local Phone Number 393-8248
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Trading Symbol SBRA
Security Exchange Name NASDAQ
XML 6 sbra-20230614_htm.xml IDEA: XBRL DOCUMENT 0001492298 2023-06-14 2023-06-14 false 0001492298 8-K 2023-06-14 SABRA HEALTH CARE REIT, INC. MD 001-34950 27-2560479 18500 Von Karman Avenue Suite 550 Irvine CA 92612 888 393-8248 false false false false Common stock, $0.01 par value SBRA NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Document and Entity Information Sheet http://www.sabrahealth.com/role/DocumentandEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports sbra-20230614.htm sbra-20230614.xsd sbra-20230614_lab.xml sbra-20230614_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sbra-20230614.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021": 23 }, "contextCount": 1, "dts": { "inline": { "local": [ "sbra-20230614.htm" ] }, "labelLink": { "local": [ "sbra-20230614_lab.xml" ] }, "presentationLink": { "local": [ "sbra-20230614_pre.xml" ] }, "schema": { "local": [ "sbra-20230614.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "sbra", "nsuri": "http://www.sabrahealth.com/20230614", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sbra-20230614.htm", "contextRef": "i5f1fe33b474a477d8284e0e2522619a0_D20230614-20230614", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12bTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.sabrahealth.com/role/DocumentandEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sbra-20230614.htm", "contextRef": "i5f1fe33b474a477d8284e0e2522619a0_D20230614-20230614", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12bTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.sabrahealth.com/role/DocumentandEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 13 0001492298-23-000016-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001492298-23-000016-xbrl.zip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